Gilead inks a billion-dollar deal for a hepatitis drug

Gilead has agreed to acquire the German drugmaker Myr Pharmaceuticals and its marketed therapy for chronic hepatitis D, also known as delta hepatitis, in a deal worth a little over $1 billion.